Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Particulate form
Patent
1992-12-11
1994-08-09
Kishore, G. S.
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Particulate form
424 4, 424484, 424493, 424497, 514568, A61K 914
Patent
active
053365070
ABSTRACT:
This invention discloses a composition comprised of nanoparticles having a non-ionic surfactant as a surface modifier adsorbed on the surface thereof and a charged phospholipid as a cloud point modifier associated therewith, which cloud point modifier is present in an amount sufficient to increase the cloud point of the surface modifier. A preferred non-ionic surfactant surface modifier is a poloxamine or tyloxapol, and preferred charged phospholipid cloud point modifiers include dimyristoyl phosphatidyl glycerol. This invention further discloses a method of making nanoparticles having a non-ionic surfactant as a surface modifier adsorbed on the surface and a charged phospholipid as a cloud point modifier associated therewith, comprised of contacting said nanoparticles with the cloud point modifier for a time and under conditions sufficient to increase the cloud point of the surface modifier.
REFERENCES:
patent: 4894234 (1990-01-01), Sharma et al.
patent: 4904479 (1990-02-01), Illum
patent: 5091188 (1992-02-01), Haynes
patent: 5145684 (1992-09-01), Liversidge et al.
patent: 5151264 (1992-09-01), Samain et al.
patent: 5188837 (1993-02-01), Domb
patent: 5396630 (1983-08-01), Riedl et al.
Na George C.
Rajagopalan Natarajan
Davis William J.
Hohenschutz Liza D.
Kishore G. S.
Sterling Winthrop Inc.
LandOfFree
Use of charged phospholipids to reduce nanoparticle aggregation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of charged phospholipids to reduce nanoparticle aggregation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of charged phospholipids to reduce nanoparticle aggregation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-214939